The latest news from academia, regulators
research labs and other things of interest
Posted: Oct 04, 2013
Nanoparticle stem cell replacement therapy for reflux nephropathy
(Nanowerk News) An EU-funded project has investigated the potential of stem cell-based replacement therapy for prevention of end stage renal disease. The work involved the design of a new type of magnetic nanoparticle to label the stem cells for in vivo tracking.
During the initial stage (first 17 months) the major goal was to develop a non-invasive method to monitor stem cells following their transplantation. Magnetic nanoparticle (MNP) labelling of the cells coupled with magnetic resonance imaging (MRI) has the advantages over other imaging techniques because the magnetic signal does not diminish with tissue depth.
However, most MNPs available to date are quickly degraded within the cellular environment. Researchers of the project prepared MNPs with a protective coating and demonstrated that these MNPs were more readily retained inside the stem cells than were commercial MNPs. RENALSTEM MNPs caused no significant cytotoxicity at concentrations of 30 micrograms per ml per 100 000 cells.
Embryonic stem cells labelled with the MNPs expressed similar levels of the pluripotency markers and expressed markers of three germ layer derivatives. Stem cells labelled with the MNPs were able to undergo osteogenesis and adipogenesis to a similar extent as unlabelled stem cells. This demonstrates that the developed MNPs had no adverse effects on pluripotency and differentiation potential of stem cells.
The results of this initial stage of the project formed the basis of a proposal to a United Kingdom stem sell initiative that was funded in March 2010. Two papers have been published in the journals of IEEE Transactions on Nanoscience (2010) and the Journal of Nanoscience and Nanotechnology (2011).
Further investigation based on RENALSTEM results would be a significant step forward in the development of stem cell based therapies in general.